GlassScriptPhysician profile
David J Goldmeier
NPI 1629121371
$4,236.83
in general payments reported to CMS, 2019-2025
27 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $561 · 2021: $253 · 2022: $1,163 · 2023: $393 · 2024: $250 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $931.63 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $789.48 | 2019-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $418.17 | 2019-2023 | Aristada, Lybalvi |
| Abbvie INC. | $377.96 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $318.06 | 2019-2023 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $252.49 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $205.38 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $195.29 | 2019-2022 | |
| Axsome Therapeutics, INC. | $96.75 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $88.56 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.50 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.03 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.27 | 2021-2022 | |
| Allergan, INC. | $59.41 | 2019-2020 | |
| Indivior INC. | $51.39 | 2019-2023 | Perseris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $29.04 | 2019 | |
| Gilead Sciences, INC. | $24.29 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.61 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.01 | 2022 | |
| Corium, LLC | $22.51 | 2022 | |
| Lundbeck LLC | $18.09 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $17.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.83 | 2022 | |
| Noven Therapeutics, LLC | $15.24 | 2022 | |
| Acadia Pharmaceuticals INC | $15.22 | 2019 | |
| Eisai INC. | $12.56 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.